TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first in class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.
Location: United States, Massachusetts, Boston
Employees: 1-10
Total raised: $32.4M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
| - | Bluestem C... | bluestemca... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.04.2022 | - | $5.9M | - |
| 12.08.2020 | Series B | $22M | - |
| 31.05.2017 | Series A | $4.5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 12.08.2020 | TearClear Raises $22M in Series B Funding | TearClear, a Boston, MA-based ophthalmic pharmaceutical company, raised $22M in a Series B funding round. Backers included Visionary Ventures, Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by... |
| 11.08.2020 | TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development | BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for futur... |
| 31.05.2017 | TearClear Closes $4.5M in Series A Funding | TearClear, an Orange County, Calif.-based eye health technology company, raised $4.5m in Series A financing. The round was co-led by Visionary Venture Fund and Bluestem Capital. In addition to the funding, William Link, PhD, who has executi... |
| - | TearClear | “Preservative-free ophthalmic drug delivery” |